FHTX
Foghorn Therapeutics Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-37/100
Last price
1.92
▼ 0.08 (4.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.97
Prev close
2.00
Day high
2.01
Day low
1.84
Volume
984.48K
Market cap
$116.99M
P/E (TTM)
—
52W range
1.79 – 7.61
Day trading desk
Gap from prior close
-1.31%
Prior close 2.00
VWAP
1.95
-1.58% from price
Relative volume
3.05×
Unusually busy
Session range
14.52%
1.84 – 2.10
Position in range
32%
Mid range
ATR (14D)
0.36
18.76% of price
Prior day high
2.12
PDH
Prior day low
1.98
PDL
Bid / ask spread
—
Quote not published
Session volume
1.87M
Avg 611.73K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-44.03%
-46.0%
1M
-59.96%
-61.1%
3M
-68.07%
-72.6%
6M
-60.36%
-78.5%
YTD
-63.52%
-77.8%
1Y
-57.54%
-74.0%
3Y
-60.60%
-142.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FHTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.39M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 10, 26 | GOTTSCHALK ADRIAN Chief Executive Officer |
STOCK | 106.70K | $0 | Indirect |
| Apr 25, 25 | GOTTSCHALK ADRIAN Chief Executive Officer |
STOCK | 300.00K | $0 | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
GOTTSCHALK ADRIAN |
Chief Executive Officer | — | Stock Gift |
Fundamentals
Market cap$116.99M
Enterprise value$-7.49M
Revenue (TTM)$36.74M
Gross profit$-42.09M
EBITDA$-66.35M
Net income$-64.58M
EPS (TTM)$-0.96
Free cash flow$-51.95M
Total cash$167.58M
Total debt$43.10M
Book value / share$-1.38
Shares outstanding59.39M
Float28.08M
Short % of float6.10%
Dividend yield0.00%
Beta (5Y)3.01
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.92
PEG ratio—
Price / sales—
Price / book—
EV / revenue-0.20
EV / EBITDA0.11
Gross margin-114.57%
Operating margin-54.78%
Profit margin-175.78%
Return on equity—
Return on assets-19.92%
Debt / equity—
Current ratio3.36
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $30.91M | $22.60M | $34.16M | $19.23M | +36.8% |
| Operating revenue | $30.91M | $22.60M | $34.16M | $19.23M | +36.8% |
| Research & development | $85.47M | $94.53M | $109.69M | $105.62M | -9.6% |
| Selling, general & admin | $27.55M | $28.36M | $32.37M | $30.75M | -2.9% |
| Total operating expense | $113.02M | $122.89M | $142.06M | $136.37M | -8.0% |
| Operating income | -$82.11M | -$100.28M | -$107.91M | -$117.14M | +18.1% |
| Net interest income | $8.74M | $11.90M | $10.88M | $5.67M | -26.5% |
| Pre-tax income | -$74.28M | -$86.62M | -$94.20M | -$108.88M | +14.2% |
| Tax provision | — | $0 | $4.23M | $0 | — |
| Net income | -$74.28M | -$86.62M | -$98.43M | -$108.88M | +14.2% |
| Net income to common | -$74.28M | -$86.62M | -$98.43M | -$108.88M | +14.2% |
| Basic EPS | -1.18 | -1.58 | -2.34 | -2.62 | +25.3% |
| Diluted EPS | -1.18 | -1.58 | -2.34 | -2.62 | +25.3% |
| EBIT | -$82.11M | -$100.28M | -$107.91M | -$117.14M | +18.1% |
| EBITDA | -$78.78M | -$97.17M | -$104.45M | -$113.82M | +18.9% |
| Basic shares | 62.98M | 54.90M | 41.97M | 41.59M | +14.7% |
| Diluted shares | 62.98M | 54.90M | 41.97M | 41.59M | +14.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.88M | $55.45M | $80.34M | $52.21M | — | +45.8% |
| Cash & short-term investments | $158.89M | $243.75M | $234.06M | $345.80M | — | -34.8% |
| Accounts receivable | — | — | — | $0 | $300.00M | — |
| Total current assets | $163.24M | $249.60M | $240.18M | $351.40M | — | -34.6% |
| Property, plant & equipment | $32.86M | $32.60M | $42.91M | $49.40M | — | +0.8% |
| Total assets | $198.10M | $283.98M | $285.92M | $404.88M | — | -30.2% |
| Total current liabilities | $59.74M | $66.99M | $58.44M | $55.20M | — | -10.8% |
| Total debt | $41.27M | $37.13M | $45.07M | $51.51M | — | +11.1% |
| Total liabilities | $306.60M | $329.51M | $363.11M | $404.77M | — | -7.0% |
| Retained earnings | -$632.47M | -$558.18M | -$471.56M | -$373.14M | — | -13.3% |
| Shareholder equity | -$108.50M | -$45.53M | -$77.19M | $112.00K | — | -138.3% |
| Working capital | $103.50M | $182.61M | $181.75M | $296.19M | — | -43.3% |
| Net tangible assets | -$108.50M | -$45.53M | -$77.19M | $112.00K | — | -138.3% |
| Shares issued | 56.66M | 55.59M | 42.28M | 41.80M | — | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$74.28M | -$86.62M | -$98.43M | -$108.88M | +14.2% |
| Depreciation & amortisation | $3.33M | $3.12M | $3.45M | $3.32M | +6.8% |
| Stock-based compensation | $10.40M | $11.89M | $16.19M | $14.34M | -12.6% |
| Change in working capital | -$32.14M | -$32.27M | -$41.88M | $281.55M | +0.4% |
| Operating cash flow | -$86.10M | -$100.41M | -$118.11M | $193.61M | +14.2% |
| Capital expenditure | -$50.00K | -$906.00K | -$1.22M | -$1.21M | +94.5% |
| Investing cash flow | $112.04M | -$29.90M | $144.45M | -$244.32M | +474.7% |
| Financing cash flow | $1.02M | $105.43M | $1.78M | $1.76M | -99.0% |
| Free cash flow | -$86.15M | -$101.31M | -$119.33M | $192.40M | +15.0% |
| End cash position | $84.13M | $57.16M | $82.04M | $53.92M | +47.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $16.07M | $3.27M | $9.25M | $8.15M | $7.56M | — | +391.9% |
| Operating revenue | $16.07M | $3.27M | $9.25M | $8.15M | $7.56M | — | +391.9% |
| Research & development | $18.52M | $18.26M | $22.05M | $20.00M | $21.79M | — | +1.4% |
| Selling, general & admin | $6.35M | $6.58M | $6.80M | $6.65M | $6.86M | — | -3.4% |
| Total operating expense | $24.88M | $24.84M | $28.84M | $26.65M | $28.65M | — | +0.1% |
| Operating income | -$8.80M | -$21.57M | -$19.60M | -$18.50M | -$21.10M | — | +59.2% |
| Net interest income | $1.61M | $1.74M | $1.71M | $2.03M | $2.31M | — | -7.6% |
| Pre-tax income | -$7.19M | -$19.88M | -$21.66M | -$15.85M | -$17.94M | — | +63.8% |
| Net income | -$7.19M | -$19.88M | -$21.66M | -$15.85M | -$17.94M | — | +63.8% |
| Net income to common | -$7.19M | -$19.88M | -$21.66M | -$15.85M | -$17.94M | — | +63.8% |
| Basic EPS | -0.10 | -0.29 | — | -0.25 | -0.28 | -0.30 | +65.5% |
| Diluted EPS | -0.10 | -0.29 | — | -0.25 | -0.28 | -0.30 | +65.5% |
| EBIT | -$8.80M | -$21.57M | -$19.60M | -$18.50M | -$21.10M | — | +59.2% |
| EBITDA | -$8.57M | -$21.34M | -$18.79M | -$17.65M | -$20.25M | — | +59.8% |
| Basic shares | 70.63M | 69.54M | — | 63.03M | 62.98M | 62.85M | +1.6% |
| Diluted shares | 70.63M | 69.54M | — | 63.03M | 62.98M | 62.85M | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $68.08M | $87.66M | $80.88M | $89.33M | $72.57M | -22.3% |
| Cash & short-term investments | $167.58M | $183.63M | $158.89M | $180.28M | $198.66M | -8.7% |
| Total current assets | $170.05M | $188.06M | $163.24M | $184.12M | $203.84M | -9.6% |
| Property, plant & equipment | $31.34M | $32.10M | $32.86M | $18.84M | $20.39M | -2.4% |
| Total assets | $203.39M | $222.17M | $198.10M | $204.96M | $226.24M | -8.5% |
| Total current liabilities | $50.58M | $64.40M | $59.74M | $85.09M | $77.79M | -21.5% |
| Total debt | $43.10M | $41.99M | $41.27M | $22.53M | $23.70M | +2.6% |
| Total liabilities | $284.43M | $298.57M | $306.60M | $294.62M | $302.89M | -4.7% |
| Retained earnings | -$659.53M | -$652.34M | -$632.47M | -$610.80M | -$594.95M | -1.1% |
| Shareholder equity | -$81.04M | -$76.41M | -$108.50M | -$89.66M | -$76.66M | -6.1% |
| Working capital | $119.47M | $123.66M | $103.50M | $99.03M | $126.06M | -3.4% |
| Net tangible assets | -$81.04M | -$76.41M | -$108.50M | -$89.66M | -$76.66M | -6.1% |
| Shares issued | 58.71M | 58.71M | 56.66M | 56.54M | 55.80M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$7.19M | -$19.88M | -$21.66M | -$15.85M | -$17.94M | — | +63.8% |
| Depreciation & amortisation | $230.00K | $238.00K | $802.00K | $852.00K | $851.00K | — | -3.4% |
| Stock-based compensation | $2.55M | $2.38M | $2.24M | $2.73M | $2.73M | — | +7.0% |
| Change in working capital | -$13.36M | -$8.19M | -$8.20M | -$6.94M | -$7.72M | — | -63.2% |
| Operating cash flow | -$17.84M | -$25.27M | -$22.27M | -$18.86M | -$21.00M | — | +29.4% |
| Capital expenditure | — | — | — | — | -$22.00K | -$28.00K | — |
| Investing cash flow | -$2.97M | -$17.72M | $13.23M | $35.57M | $33.83M | — | +83.3% |
| Financing cash flow | -$22.00K | $49.77M | $581.00K | $49.00K | $254.00K | — | -100.0% |
| Free cash flow | -$17.89M | -$25.27M | -$22.27M | -$18.86M | -$21.02M | — | +29.2% |
| End cash position | $70.08M | $90.91M | $84.13M | $92.58M | $75.82M | — | -22.9% |
Options analytics
Put / call volume
14.51
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+26.9% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
37
Contracts, this expiry
Put volume
537
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.23 | -0.10 | +57.1% |
| Mar 2026 | -0.31 | -0.29 | +7.2% |
| Dec 2025 | -0.26 | -0.37 | -42.4% |
| Sep 2025 | -0.30 | -0.25 | +16.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.25 | 7 | $7.10M | -12.9% |
| Next quarter | -0.25 | 7 | $3.34M | -63.9% |
| Current year | -0.93 | 8 | $28.71M | -7.1% |
| Next year | -1.03 | 8 | $10.79M | -62.4% |
Analyst targets & ownership
Mean target$6.00
High target$14.00
Low target$2.00
Implied upside212.50%
Analyst count6
ConsensusBUY
Strong buy / Buy0 / 6
Hold4
Sell / Strong sell0 / 0
Held by insiders14.13%
Held by institutions77.11%
Institutions holding138
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.05
-37.03% from price
SMA 20
3.67
-46.36% from price
SMA 50
4.99
-60.49% from price
SMA 100
4.76
-59.65% from price
SMA 200
5.02
-60.76% from price
EMA 12
3.06
-37.35% from price
EMA 26
3.86
-50.22% from price
EMA 50
4.43
-56.68% from price
RSI (14)
12.3
Oversold
MACD (12,26,9)
-0.79
Hist -0.17
ATR (14)
0.36
18.29% of price
Realised vol 30D
119.0%
Annualised
Bollinger upper
5.30
20, 2σ
Bollinger lower
2.04
20, 2σ
50 / 200 cross
Death
4.99 vs 5.02
Trend bias
Below 200
-60.76%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.66
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
119.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-72.1%
Peak to trough
Max drawdown 5Y
-91.4%
Peak to trough
ATR 14
0.36
18.29% of price
Beta (reported)
3.01
5Y monthly, from filing
Short interest
Shares short
1.99M
Prior 1.79M
Change vs prior
+11.5%
Shorts adding
% of float
6.10%
Normal
% of shares out
3.36%
Against total outstanding
Days to cover
4.9
Liquid
Float
28.08M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Oct 2, 26 | TD Cowen | DOWNGRADE | Buy | Hold |
| Oct 2, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Oct 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 2, 26 | BTIG | DOWNGRADE | Buy | Neutral |
| Mar 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 17, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Dec 18, 25 | BTIG | INITIATED | — | Buy |
| Dec 4, 25 | Stifel | INITIATED | — | Buy |
| Nov 7, 25 | Guggenheim | INITIATED | — | Buy |
| May 15, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-21
Offering Registrations
S-8 · 2026-03-26
Periodic Financial Reports
10-K · 2026-03-11
Headlines
Foghorn Therapeutics Shares Fall After Wedbush Downgrade
MT Newswires · 4d ago
Top Midday Decliners
MT Newswires · 4d ago
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
Stocktwits · 4d ago
Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
Quartz · 5d ago
Correction: Top Midday Decliners
MT Newswires · 5d ago
Wedbush Downgrades Foghorn Therapeutics to Neutral From Outperform, Cuts Price Target to $2 From $10
MT Newswires · 5d ago
TD Cowen Downgrades Foghorn Therapeutics to Hold From Buy
MT Newswires · 5d ago
BTIG Downgrades Foghorn Therapeutics to Neutral From Buy
MT Newswires · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.